Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barre´ syndrome

Stephen Keddie, J.Pakpoor, C.Mousele, M.Pipis, P.M. Machado, M.Foster, C.J. Record, R.Y. S. Keh, J.Fehmi, R.W. Paterson, V.Bharambe, L.M. Clayton, C.Allen, O.Price, J.Wall, A.Kiss-Csenki, D.P.Rathnasabapathi, R.Geraldes, T.Yermakova, J.King-Robson, M.Zosmer, S.Rajakulendran, S.Sumaria, S.F. Farmer, R.Nortley, C.R. Marshall, E.J. Newman, N.Nirmalananthan, G.Kumar, A.A. Pinto, J.Holt, T.M. Lavin, K.M. Brennan, M.S. Zandi, D.L Jayaseelan, J.Pritchard, R.D. M Hadden, H. Manji, H. J. Willison, S. Rinaldi, A. S. Carr, M.P Lunn

Brain, Volume 144, Issue 2, February 2021, Pages 682–693, https://doi.org/10.1093/brain/awaa433

MOTIVATION: This epidemiological and cohort study investigated any causative association between COVID-19 infection and GBS. Findings indicate no epidemiological or phenotypic clues of SARS-CoV-2 being causative of GBS. The authors also recorded a decrease in GBS incidence during the pandemic, which may be the influence of lockdown measures reducing transmission of GBS inducing pathogens such as Campylobacter jejuni and respiratory viruses.
The study provides novel and unknown information on a issue of interest for the entire medical community